T1	outcome 922 925	DFS
T2	iv-bin-percent 1042 1047	84.3%
T3	cv-bin-percent 1060 1065	69.4%
T4	outcome 778 811	5-year overall survival rate (OS)
T5	outcome 820 859	5-year disease-free survival rate (DFS)
T6	total-participants 692 695	136
T7	intervention-participants 713 715	68
T8	control-participants 734 736	68
T10	intervention 0 85	1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen
T11	control 361 370	CMF + TAM
T9	eligibility 493 596	Clinical stage I, II primary breast cancers with histologically positive axillary lymph node metastasis
T12	outcome 1144 1159	adverse effects
T13	outcome 1368 1371	QOL
T14	outcome 1228 1243	adverse effects
T15	outcome 1382 1391	lassitude
T16	outcome 1393 1427	degree of difficulty in daily life
T17	outcome 1429 1456	satisfaction with treatment
T18	outcome 1461 1473	present mood
